SUBSCRIBERS
AstraZeneca slumps on report CEO is heading to Teva
Published Thu, Jul 13, 2017 · 09:50 PM
'%3e%3cpath%20d='M20.7725%2026.9924C20.9555%2026.9924%2021.1297%2026.953%2021.2951%2026.8741C21.4604%2026.7953%2021.6346%2026.6694%2021.8177%2026.4965L27.8373%2020.8125C27.9848%2020.6752%2028.0865%2020.5353%2028.1425%2020.3929C28.1985%2020.2505%2028.2264%2020.1183%2028.2264%2019.9962C28.2264%2019.869%2028.1985%2019.7343%2028.1425%2019.5918C28.0865%2019.4494%2027.9848%2019.3095%2027.8373%2019.1722L21.8177%2013.5417C21.6142%2013.3484%2021.4375%2013.2098%2021.2875%2013.1259C21.1374%2013.042%2020.9708%2013%2020.7877%2013C20.5181%2013%2020.2981%2013.0916%2020.1278%2013.2747C19.9574%2013.4578%2019.8722%2013.6765%2019.8722%2013.9308V16.8147H19.6509C18.2827%2016.8147%2017.1014%2017.0258%2016.107%2017.448C15.1127%2017.8701%2014.2963%2018.4805%2013.658%2019.279C13.0197%2020.0776%2012.5466%2021.0402%2012.2389%2022.1668C11.9312%2023.2934%2011.7773%2024.5612%2011.7773%2025.9701C11.7773%2026.3006%2011.8575%2026.5537%2012.0177%2026.7291C12.1779%2026.9047%2012.3597%2026.9924%2012.5632%2026.9924C12.7259%2026.9924%2012.89%2026.9593%2013.0553%2026.8932C13.2206%2026.8271%2013.3693%2026.6719%2013.5016%2026.4278C13.9441%2025.5936%2014.4553%2024.9413%2015.0351%2024.4708C15.6149%2024.0004%2016.2838%2023.6685%2017.0417%2023.4752C17.7995%2023.2819%2018.6693%2023.1853%2019.6509%2023.1853H19.8722V26.0998C19.8722%2026.3591%2019.9574%2026.5728%2020.1278%2026.7406C20.2981%2026.9085%2020.513%2026.9924%2020.7725%2026.9924Z'%20fill='black'%20fill-opacity='0.85'/%3e%3c/g%3e%3crect%20x='0.5'%20y='0.5'%20width='39'%20height='39'%20rx='19.5'%20stroke='%23F2F2F2'/%3e%3cdefs%3e%3cclipPath%20id='clip0_715_28555'%3e%3crect%20width='16.4491'%20height='14'%20fill='white'%20transform='translate(11.7773%2013)'/%3e%3c/clipPath%3e%3c/defs%3e%3c/svg%3e){kind=small}
London
SHARES in AstraZeneca fell more than 5 per cent on Thursday after the company declined to deny a media report that chief executive Pascal Soriot was about to defect to Israel-based Teva Pharmaceutical Industries.
Mr Soriot, who has led the Anglo- Swedish company since 2012, met Teva's search committee and its chairman to express his agreement to serve as its next CEO, the Calcalist financial news website said late on Wednesday.
'/%3e%3cpath%20d='M35.1847%2014.0422L9.37867%2024.1703C8.88772%2024.363%208.86989%2025.051%209.35015%2025.2688L15.0551%2027.8567C15.2097%2027.9269%2015.327%2028.0594%2015.3778%2028.2212L17.8255%2036.0078C17.9491%2036.4009%2018.4247%2036.5534%2018.7539%2036.3054L23.0143%2033.0968C23.2178%2032.9435%2023.4961%2032.9364%2023.7072%2033.0787L30.8526%2037.8975C31.2091%2038.1378%2031.6951%2037.9339%2031.7732%2037.5114L35.9896%2014.7059C36.0747%2014.2456%2035.6206%2013.8712%2035.1847%2014.0422Z'%20fill='%23FDFEFF'/%3e%3cpath%20d='M15.3125%2027.9998L30.4162%2018.627L19.3691%2029.3628L19.548%2033.3966L18.9531%2036.1248C18.3783%2036.7236%2017.9297%2036.2772%2017.8477%2036.0662L15.3681%2028.178L15.2734%2028.0233L15.3125%2027.9998Z'%20fill='%23C8DAEA'/%3e%3cpath%20d='M18.3594%2036.4259L19.3511%2029.3447L23.519%2032.9856C23.303%2032.9612%2023.1588%2032.9863%2023.0268%2033.0859L19.0712%2036.0718C18.6289%2036.4572%2018.4297%2036.4455%2018.3594%2036.4259Z'%20fill='%23A9C9DD'/%3e%3cdefs%3e%3clinearGradient%20id='paint0_linear'%20x1='33'%20y1='7.5'%20x2='19'%20y2='36.5'%20gradientUnits='userSpaceOnUse'%3e%3cstop%20stop-color='%231E96C8'/%3e%3cstop%20offset='1'%20stop-color='%2337AEE2'%20stop-opacity='0'/%3e%3c/linearGradient%3e%3c/defs%3e%3c/svg%3e)
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Billionaire Geiger is said to near US$7 billion L’Occitane buyout
HCA beats first-quarter profit estimates on higher patient admissions
US FDA approves Pfizer’s gene therapy for rare bleeding disorder
EU toughens rules on Chinese fashion retailer Shein
Best World under fire from shareholders at AGM over dividends, director salaries
‘Extreme’ climate blamed for world’s worst wine harvest in 62 years
